<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546051</url>
  </required_header>
  <id_info>
    <org_study_id>BCI-632-CL-002</org_study_id>
    <nct_id>NCT01546051</nct_id>
  </id_info>
  <brief_title>A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainCells Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainCells Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its
      metabolite BCI-632 and several new pro-drugs in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase of this study will evaluate the safety and tolerability of BCI-838 following
      oral administration of single doses of BCI-838 in healthy male subjects. The pharmacokinetics
      of BCI-838 and its metabolite BCI-632 following single ascending doses of BCI-838 will be
      evaluated, as will the effect of food on the pharmacokinetics of BCI-838 and its metabolite
      following single oral doses of BCI-838 in healthy male subjects.

      The second phase of this study will evaluate and compare the relative bioavailability and PK
      of the metabolite BCI-632 following single oral administration of several new pro-drug
      candidates in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>7 days</time_frame>
    <description>Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632</measure>
    <time_frame>predose and at specified intervals up to 72 hours post-dose</time_frame>
    <description>The pharmacokinetics of BCI-838 and its metabolite BCI-632, an assessment of the dose proportionality of the pharmacokinetics following single ascending doses of BCI-838, and an evaluation of the relative bioavailability and pharmacokinetics of the metabolite BCI-632 following oral administration of several new pro-drug candidates will be completed by assessment of Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BCI-838 Food Effect Dosing Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Fasted Dosing (100 &amp; 300 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-1038, BCI-1206 &amp; BCI-1283</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCI-838 Fasted Dosing (900 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design</description>
    <arm_group_label>BCI-838 Fasted Dosing (100 &amp; 300 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design</description>
    <arm_group_label>BCI-838 Food Effect Dosing Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-1038, BCI-1206 &amp; BCI-1283</intervention_name>
    <description>Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design</description>
    <arm_group_label>BCI-1038, BCI-1206 &amp; BCI-1283</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCI-838</intervention_name>
    <description>BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions</description>
    <arm_group_label>BCI-838 Fasted Dosing (900 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male healthy volunteer, 18-55 years of age

          -  Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive

          -  Good general health as determined by medical history and physical examination with no
             clinically significant medical findings and no clinically relevant medical or surgical
             history and no acute or ongoing conditions within the past 30 days

          -  Able to participate and willing to give written informed consent and to comply with
             the study restrictions

        Exclusion Criteria:

          -  Clinically significant medical abnormality, chronic disease or history or presence of
             significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or
             neurological disorder

          -  History or current use of alcohol abuse or drug addiction

          -  Participation in a drug study within 60 days prior to drug administration.

          -  Participation in more than 3 other drug studies in the 10 months preceding the start
             of this study

          -  Donation or blood loss of more than 50 mL of blood within 60 days prior to the first
             drug administration. Donation of more than 1.5 liters of blood in the 10 months
             preceding the start of this study

          -  Illness within 5 days prior to drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabotropic glutamate receptors 2 and 3</keyword>
  <keyword>antagonist</keyword>
  <keyword>mGluR</keyword>
  <keyword>ketamine</keyword>
  <keyword>BDNF</keyword>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Mood Disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Phase 1 safety, tolerability and pharmacokinetics study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

